Literature DB >> 16902154

siRNA silencing of calumenin enhances functional factor IX production.

Nadeem Wajih1, Susan M Hutson, Reidar Wallin.   

Abstract

To improve production of functional fully gamma-carboxylated recombinant human clotting factor IX (r-hFIX), cell lines stably overexpressing r-hFIX have been engineered to also overexpress proteins of the gamma-carboxylation system. Here we demonstrate that siRNA silencing of calumenin, an inhibitor of the gamma-carboxylation system, enhances production of functional r-hFIX produced by engineered BHK21 cells. The production yield of functional r-hFIX was 80% in engineered cells where calumenin had been silenced 78%. We propose that this high-yield expression system can easily be adapted to overproduce functional forms of all members of the vitamin K-dependent protein family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902154      PMCID: PMC1895465          DOI: 10.1182/blood-2006-02-004671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Molecular and cellular biology of blood coagulation.

Authors:  B Furie; B C Furie
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

2.  A molecular mechanism for genetic warfarin resistance in the rat.

Authors:  R Wallin; S M Hutson; D Cain; A Sweatt; D C Sane
Journal:  FASEB J       Date:  2001-09-17       Impact factor: 5.191

3.  Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.

Authors:  Nadeem Wajih; Susan M Hutson; John Owen; Reidar Wallin
Journal:  J Biol Chem       Date:  2005-07-19       Impact factor: 5.157

4.  r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.

Authors:  Kevin W Hallgren; Wen Qian; Anna V Yakubenko; Kurt W Runge; Kathleen L Berkner
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

Review 5.  The CREC family, a novel family of multiple EF-hand, low-affinity Ca(2+)-binding proteins localised to the secretory pathway of mammalian cells.

Authors:  B Honoré; H Vorum
Journal:  FEBS Lett       Date:  2000-01-21       Impact factor: 4.124

6.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

7.  Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X.

Authors:  Yan-Mei Sun; Da-Yun Jin; Rodney M Camire; Darrel W Stafford
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

8.  Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

Authors:  D A Roth; C M Kessler; K J Pasi; B Rup; S G Courter; K L Tubridy
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

Review 9.  Recombinant factor VIIa (Novoseven) as a hemostatic agent.

Authors:  U Hedner
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

10.  In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells.

Authors:  A Rehemtulla; D A Roth; L C Wasley; A Kuliopulos; C T Walsh; B Furie; B C Furie; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more
  5 in total

1.  Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.

Authors:  Nadeem Wajih; John Owen; Reidar Wallin
Journal:  Thromb Res       Date:  2008-01-03       Impact factor: 3.944

2.  Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?

Authors:  Ingrid Glurich; Richard L Berg; James K Burmester
Journal:  Clin Med Res       Date:  2013-05-08

3.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

4.  Calumenin knockdown, by intronic artificial microRNA, to improve expression efficiency of the recombinant human coagulation factor IX.

Authors:  Javad Parnian; Maryam Hoseindokht; Zahra Khademi; Maedeh Moosavi; Zahra Soheila Soheili; Shahram Samie; Alireza Zomorodipour
Journal:  Biotechnol Lett       Date:  2022-04-12       Impact factor: 2.461

5.  Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.

Authors:  Marwa Ajmi; Asma Omezzine; Slim Achour; Dorra Amor; Haithem Hamdouni; Fatma Ben Fredj Ismaïl; Nabila Ben Rejeb; Chedia Laouani Kechrid; Essia Boughzela; Ali Bouslama
Journal:  Eur J Clin Pharmacol       Date:  2018-02-26       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.